Adverse events during treatment among 195 patients, by rifampicin-resistant tuberculosis treatment regimen
| Cohort | ||||||||
| Total | STR unmodified | STR modified during treatment | STR modified from start | |||||
| Total n | 195 | 162 | 16 | 17 | ||||
| AE during treatment (any) | ||||||||
| No AE during treatment | 19 (9.7) | 18 (11.1) | 0 (0) | 1 (5.9) | ||||
| Grade 1 | 81 (41.5) | 75 (46.3) | 3 (18.8) | 3 (17.6) | ||||
| Grade 2 | 86 (44.1) | 69 (42.6) | 7 (43.8) | 10 (58.8) | ||||
| Grade 3 | 9 (4.6) | 0 (0) | 6 (37.5) | 3 (17.6) | ||||
| Grade 4 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Ototoxicity | ||||||||
| Present at baseline | 19 (9.7) | 2 (1.2) | 0 (0) | 17 (100) | ||||
| Not during treatment | 124 (63.6) | 124 (76.5) | 0 (0) | 0 (0) | ||||
| Grade 1 | 35 (17.9) | 31 (19.1) | 4 (25) | 0 (0) | ||||
| Grade 2 | 15 (7.7) | 5 (3.1) | 10 (62.5) | 0 (0) | ||||
| Grade 3 | 2 (1) | 0 (0) | 2 (12.5) | 0 (0) | ||||
| Nephrotoxicity | ||||||||
| Not during treatment | 182 (93.3) | 152 (93.8) | 13 (81.3) | 17 (100) | ||||
| Grade 1 | 11 (5.6) | 8 (4.9) | 3 (18.8) | 0 (0) | ||||
| Grade 2 | 2 (1) | 2 (1.2) | 0 (0) | 0 (0) | ||||
| Bone marrow suppression | ||||||||
| Not during treatment | 176 (90.3) | 161 (99.4) | 9 (56.3) | 6 (35.3) | ||||
| Grade 1 | 4 (2.1) | 0 (0) | 3 (18.8) | 1 (5.9) | ||||
| Grade 2 | 9 (4.6) | 1 (0.6) | 1 (6.3) | 7 (41.2) | ||||
| Grade 3 | 6 (3.1) | 0 (0) | 3 (18.8) | 3 (17.6) | ||||
| Peripheral neuropathy | ||||||||
| Not during treatment | 168 (86.2) | 145 (89.5) | 12 (75) | 11 (64.7) | ||||
| Grade 1 | 10 (5.1) | 7 (4.3) | 3 (18.8) | 0 (0) | ||||
| Grade 2 | 17 (8.7) | 10 (6.2) | 1 (6.3) | 6 (35.3) | ||||
| Gastrointestinal toxicity | ||||||||
| No AE during treatment | 39 (20) | 34 (21) | 3 (18.8) | 2 (11.8) | ||||
| Grade 1 | 99 (50.8) | 84 (51.9) | 11 (68.8) | 4 (23.5) | ||||
| Grade 2 | 57 (29.2) | 44 (27.2) | 2 (12.5) | 11 (64.7) | ||||
| Hepatotoxicity | ||||||||
| No AE during treatment | 140 (71.8) | 121 (74.7) | 8 (50) | 11 (64.7) | ||||
| Grade 1 | 39 (20) | 30 (18.5) | 5 (31.3) | 4 (23.5) | ||||
| Grade 2 | 14 (7.2) | 11 (6.8) | 1 (6.3) | 2 (11.8) | ||||
| Grade 3 | 2 (1) | 0 (0) | 2 (12.5) | 0 (0) | ||||
Data are presented n (%), unless otherwise stated. AE: adverse event; STR: shorter treatment regime.